InsidersTradesSigma
Ikena Oncology, Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the Ikena Oncology, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Ikena Oncology, Inc. has recorded 16 public disclosures. The latest transaction was disclosed on 21 September 2023 (Attribution). Among the most active insiders: Zhang Xiaoyan Michelle. Every trade is free.
16
Insider Decl.
0
Thresholds
€7m
6 ops.
Buy Volume
·
0 ops.
Sell Volume
35Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 21 September 2023
Declarations16 total
153,121 sharesNon-Voting Common StockSEC:0000947871-23-000952:0
153,121 sharesNon-Voting Common StockSEC:0000947871-23-000951:0
153,121 sharesCommon StockSEC:0000947871-23-000932:0
153,121 sharesCommon StockSEC:0000947871-23-000931:0
66,806 shares@ US$3.55100.0% of flowCommon StockSEC:0000947871-22-000721:0
Ideal exit: 19 Mar 2023 (T+270)
66,806 shares@ US$3.55100.0% of flowCommon StockSEC:0000947871-22-000722:0
Ideal exit: 19 Mar 2023 (T+270)
38,915 shares@ US$2.9450.0% of flowCommon StockSEC:0000899243-22-002657:0
38,915 shares@ US$2.94100.0% of flowCommon StockSEC:0000899243-22-002657
36 shares@ US$2.14623.5% of flowCommon StockSEC:0000899243-22-001806
36 shares@ US$2.14621.7% of flowCommon StockSEC:0000899243-22-001806:0
125,000 shares@ US$16.0050.0% of flowCommon StockSEC:0001209191-21-069645:0
Ideal exit: 25 Dec 2021 (T+270)
125,000 shares@ US$16.0050.0% of flowCommon StockSEC:0001209191-21-069644:0
Ideal exit: 25 Dec 2021 (T+270)
1,000 shares@ US$2.146248.3% of flowCommon StockSEC:0000899243-21-048230:0
1,000 shares@ US$2.146296.5% of flowCommon StockSEC:0000899243-21-048230
125,000 shares@ US$16.00100.0% of flowCommon StockSEC:0001209191-21-069645
Ideal exit: 25 Dec 2021 (T+270)
125,000 shares@ US$16.00100.0% of flowCommon StockSEC:0001209191-21-069644
Ideal exit: 25 Dec 2021 (T+270)
16 of 16 declarations
About Ikena Oncology, Inc.
Ikena Oncology, Inc. was a United States-based biotechnology company listed on the Nasdaq market (NYSE/NASDAQ), with corporate operations centered in Boston, Massachusetts, United States. Historically, the company was positioned as a precision oncology developer focused on targeted therapies for biomarker-defined and genetically defined cancer subpopulations. Founded as a private biotech before going public in 2021, Ikena built its investment case around biology-driven programs aimed at signaling pathways that control tumor growth, spread, and therapeutic resistance. ([ir.ikenaoncology.com](https://ir.ikenaoncology.com/news-releases/news-release-details/ikena-oncology-announces-pricing-initial-public-offering/?utm_source=openai)) At the core of the company’s strategy was a clinical-stage pipeline featuring IK-930, a TEAD1-selective Hippo-pathway inhibitor, and IK-595, a MEK-RAF molecular glue designed to more fully suppress RAS signaling. Ikena also emphasized hard-to-treat oncology settings, particularly cancers driven by RAS/RAF alterations or Hippo-pathway dysregulation. That made the company a niche competitor in precision oncology: scientifically differentiated, but also highly dependent on clinical execution, regulatory progress, and access to capital. In practice, Ikena competed not only with other development-stage biotech names, but also indirectly with larger pharmaceutical groups that can move faster on trials, partnerships, or commercialization. ([ikenaoncology.com](https://ikenaoncology.com/pipeline/?utm_source=openai)) Geographically, Ikena operated primarily from Boston, leveraging the city’s deep biotechnology ecosystem for research, development, and corporate functions. As a U.S.-listed public company on Nasdaq, it relied heavily on equity markets and balance-sheet discipline to fund a pipeline that had not yet generated product revenue. SEC filings also reference Boston office, lab, and animal-care facilities, underscoring the company’s R&D-heavy footprint rather than a commercial manufacturing model. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1835579/000095017025034188/ikna-20241231.htm?utm_source=openai)) Recent corporate developments were material. In May 2024, Ikena announced it was discontinuing the clinical IK-930 program and concentrating resources on IK-595 while evaluating strategic alternatives to maximize shareholder value. That process ultimately culminated in a merger with Inmagene Biopharmaceuticals, completed on July 25, 2025. Following closing, Ikena Oncology changed its name to ImageneBio, Inc., and the shares began trading on Nasdaq under the new ticker IMA rather than IKNA. For investors analyzing historical Ikena filings, including SEC Form 4 insider transactions, this is an important context point: the legacy Ikena entity underwent a major strategic and corporate transformation in 2025. ([ir.ikenaoncology.com](https://ir.ikenaoncology.com/news-releases/news-release-details/update-ikena-oncology-announces-strategic-update?utm_source=openai))
